Rubius Therapeutics, Inc. (NASDAQ: RUBY) observed a climb of 11.54% on 01 NOV 2019 trading period with closing price of $9.86. The company’s last traded volume of 366350 shares vs to an average volume of 271.94K shares. The stock as of last trading session moved at 37.71% from its 52-week low and was trading at -58.88% to its 52-week high.
Entrada Therapeutics recently reported the appointment of Nathan J. Dowden as Chief Operating Officer. Mr. Dowden was most recently Senior Vice President of Strategy and Corporate Development at Rubius Therapeutics (RUBY) and joins Entrada with almost 30 years of strategy, investment and operational experience in the healthcare field.
“Nate brings an extensive track record of both planned and operational expertise from his time spent as a life sciences strategy consultant and the role he has played in the start-up and growth of several successful biotechnology companies,” stated Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. “He joins Entrada at a pivotal stage in our Company’s growth trajectory and we look forward to having his leadership on our executive team.”
“Entrada was founded upon pioneering science in the field of intracellular biologics, which have broad-ranging applications from enzyme replacement and nucleic acid therapies in rare diseases to protein degradation in cancer,” stated Mr. Dowden. “I am excited to be joining Entrada and look forward to working with Dipal and the rest of the team to shape the Company’s strategy as we progress our lead program and build out the pipeline.”
The volatility in the previous week has experienced by 8.42% and observed of 7.46% in the previous month. 91.97% ownership is held by institutional investors while insiders hold ownership of 2.60%. In the trailing 12 months period, return on assets ratio of the Company was -27.70% and return on equity ratio was -33.00%.
)
